These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 21911727)

  • 1. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
    Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
    J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma.
    Ramaswamy V; Northcott PA; Taylor MD
    Cancer Genet; 2011 Nov; 204(11):577-88. PubMed ID: 22200083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
    Fellay CN; Frappaz D; Sunyach MP; Franceschi E; Brandes AA; Stupp R
    Curr Opin Neurol; 2011 Dec; 24(6):626-32. PubMed ID: 22027544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult medulloblastoma comprises three major molecular variants.
    Remke M; Hielscher T; Northcott PA; Witt H; Ryzhova M; Wittmann A; Benner A; von Deimling A; Scheurlen W; Perry A; Croul S; Kulozik AE; Lichter P; Taylor MD; Pfister SM; Korshunov A
    J Clin Oncol; 2011 Jul; 29(19):2717-23. PubMed ID: 21632505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medulloblastoma comprises four distinct molecular variants.
    Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
    J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
    Milde T; Oehme I; Korshunov A; Kopp-Schneider A; Remke M; Northcott P; Deubzer HE; Lodrini M; Taylor MD; von Deimling A; Pfister S; Witt O
    Clin Cancer Res; 2010 Jun; 16(12):3240-52. PubMed ID: 20413433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].
    Frühwald MC; O'Dorisio MS; Smith L; Dai Z; Wright FA; Paulus W; Jürgens H; Plass C
    Klin Padiatr; 2001; 213(4):197-203. PubMed ID: 11528554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.
    de Haas T; Hasselt N; Troost D; Caron H; Popovic M; Zadravec-Zaletel L; Grajkowska W; Perek M; Osterheld MC; Ellison D; Baas F; Versteeg R; Kool M
    Clin Cancer Res; 2008 Jul; 14(13):4154-60. PubMed ID: 18593994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk stratification in medulloblastoma: screening for molecular markers].
    Ebinger M; Senf L; Scheurlen W
    Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
    Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
    Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.
    McCall TD; Pedone CA; Fults DW
    Cancer Res; 2007 Jun; 67(11):5179-85. PubMed ID: 17545597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
    Carlsson E; Krohn K; Ovaska K; Lindberg P; Häyry V; Maliniemi P; Lintulahti A; Korja M; Kivisaari R; Hussein S; Sarna S; Niiranen K; Hautaniemi S; Haapasalo H; Ranki A
    Genes Chromosomes Cancer; 2013 Feb; 52(2):191-201. PubMed ID: 23097141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.